期刊文献+

氯吡格雷预防冠心病介入治疗心血管不良事件的疗效探讨

下载PDF
导出
摘要 目的:本文旨在分析冠心病介入救治病人心血管不良事件的情况下,选择氯吡格雷药品的预防效用.方法:实验对象选择于2017年6月至2018年6月之间,在本医院进行医治的68名患有冠心病的病人,随机平均分成参考组以及实验组,每组34人.参考组病人选择噻氯匹定药品,实验组病人选择氯吡格雷,以此药品对心血管不良事件进行预防,然后分析预防成果.结果:以血栓素B2指标角度出发,实验开始之前,参考组与实验组之间无显著差距(P>0.05),满足实验条件;吃药之后6小时与24小时血栓素B2指标存在显著差距(P<0.05);同时参考组病人术后心血管不良事件发生概率为24.32%,显著超过实验组病人的5.41%(P<0.05).结论:依靠氯Ⅱ比格雷为冠心病介入治疗病人医治半年,确实能够使血栓素B2水平下降,还能降低手术之后产生心血管不良事件的概率,应该大范围使用.
作者 汪锐
出处 《医学食疗与健康》 2019年第10期279-279,共1页 Medical Diet and Health
  • 相关文献

二级参考文献30

  • 1Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) [J]. European heart journal, 2012,33 (13) : 1635-1701.
  • 2Ryden L,Grant PJ,Anker SD,et al. ESC Guidelines on diabetes,pre-diabetes and cardiovascular diseases devel- oped in collaboration with the EASD [J]. European heart journal, 2013,34(39) : 3035-3087.
  • 3Darlington A, Te!lo-Montoliu A, Rollini F, et al. Pharmac- odynamic effects of standard dose prasugrel versus high dose clopidogre! in non-diabetic obese patients with coronary artery disease [J]. Thromb Haemost, 2014,111 (2) : 258-265.
  • 4Angiolillo D J, Jakubowski JA, Ferreiro JL, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease [J]. Journal of the American College of Cardiology, 2014, 64 (10): 1005-1014.
  • 5Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease [J]. European heart journal, 2013,34 (38) : 2949 - 3003.
  • 6Roe MT,Armstrong PW,Fox KAA,et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascul- arization [J]. New England Journal of Medicine, 2012,367 (14) : 1297-1309.
  • 7Thukkani AK,Agrawal K,Prince L,et al. Long-term outcomes in patients with diabetes mellitus related to prolonging clopidogrel more than 12 months after coronary stenting [J]. Journal of the American College of Cardiology,2015,66 (10) : 1091-1101.
  • 8Andersson C,Lyngbaek S,Nguyen CD,et al. Association of clopidogrel treatment with risk of mortality and cardi- ovascular events following myocardial infarction in patients with and without diabetes [J]. JAMA,2012,308(9):882- 889.
  • 9Siller-Matula JM, Delle -Karth G, Christ G,et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-re- sponsiveness to clopidogrel or aspirin [J]. International journal of cardiology, 2013,167 (2) : 430-435.
  • 10Popma JJ, Berger P, Ohman EM, et al. Antithrombotic thera- py during percutaneous coronary intervention:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Ther- apy [ J ]. Chest, 2005,14 ( 2 ) :46.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部